Nabilone is an effective oral anti-emetic drug for moderately toxic chemotherapy, but the range and unpredictability of its side-effects warrant caution in its use.
Gastrointestinal toxicity is frequently a limiting factor in the acceptability of cancer chemotherapy to both patients and physicians (Anonymous, 1979) . Nausea and vomiting may be so severe as to adversely affect quality of life and reduce compliance with treatment (Laszlo & Lucas, 1981) . Anecdotal reports that smoking marijuana could reduce nausea caused by cytotoxics prompted studies in the United States which showed that A9-THC, the major psychoactive constituent of cannabis, possessed significant anti-emetic properties (Sallan et al., 1975; Laszlo, 1979) . However, the incidence of psychotropic and to a lesser extent cardiovascular side-effects, and its poor oral efficacy, have limited the use of A9-THC (Frytak et al., 1979) . Nabilone, a synthetic derivative of cannabis, is structurally different from natural cannabinoids, possessing a dimethyl-heptyl side-chain which prevents its chemical conversion into A9-THC (Lemberger & Rowe, 1975) . Early studies of nabilone demonstrated useful anti-emetic activity but with a high incidence of cannabinoid sideeffects; however these were conducted in mixed groups of patients with various malignancies and cytotoxic regimes and who may also have had prior experience of both emesis-inducing chemotherapy and marijuana (Herman et al., 1979; Steele et al., 1980) . The present study was designed to evaluate the efficacy and toxicity of nabilone compared with oral prochlorperazine in a histologically homogeneous group of new patients with lung cancer receiving identical chemotherapy.
Methods

Subjects
Thirty-four consecutive patients, including 15 females, with small cell bronchial carcinoma who were eligible for chemotherapy were studied. The median age was 58 years and all but one had an admission ECOG performance status of 3 or less. There were no patients with active psychiatric disease. Patients were informed of the nature and potential adverse-effects of the chemotherapy and that two different anti-emetic agents were under assessment. The relation of nabilone to cannabis was not disclosed, and it was thought that none of the patients had prior experience of marijuana.
Details of the patients are given in Table I A double-blind, double-dummy design was used, with patients receiving by random allocation either nabilone or prochlorperazine on the first cycle, and crossing over on the second course. Nabilone dosage was 2 x 1 mg capsules at 10.00 am and 10.00pm; prochlorperazine dosage was *2 x 5mg tablets at 6.00am, 2.00pm and 10.00pm. On the third or subsequent cycles of chemotherapy patients were treated with the anti-emetic agent of their choice. If a patient experienced severe nausea or vomiting in spite of the study drug, parenteral treatment with metoclopramide 10mg or chlorpromazine 50mg was given as required and the number of doses recorded.
Assessments
Symptoms With each anti-emetic course the subjects completed a self-rating symptom questionnaire, covering anorexia, nausea, retching and vomiting for the week before chemotherapy and for each of the 3 treatment days. Each symptom was graded into 4 categories, scored on a 0-3 scale with 3 representing the worst category. In addition patients were asked to report any sideeffects and if these were not spontaneously offered, specific questions were asked about them on completion of the questionnaire. At the end of the second cycle patients were asked their preference for the first or second regime, taking into account both anti-emetic and any side-effects.
Physical Blood pressure in the erect and supine positions and pulse rate were recorded just before the first dose of anti-emetic at 10.00pm on Day 0, ("0"=2, "I"= 10, "2"= 14, "3"=7, "4"= 1) 1 h afterwards and therafter twice daily. The number of vomiting episodes was recorded but the volume of vomitus was not routinely measured.
Statistical methods
Symptom scores were analysed by the MannWhitney U test. The binomial test was used to analyse preferences between the two active drugs, and the number of vomiting episodes on either. Blood pressure -data was analysed by the independent t-test. The effect of order of drug administration on preference was studied using Fisher's exact test. All probability values given are for two-tailed tests; significance accepted when P ( 0.05.
Results
Of the 34 patients entered, 6 dropped out after the first course (5 died during the first cycle of chemotherapy, one was withdrawn from chemotherapy after review of histology-see Table   II ), and 2 patients did not complete a course because of adverse effects, leaving 26 patients who completed the crossover. All but 4 of these entered the study on their first cycle of chemotherapy; the 4 had received one prior cycle with standard phenothiazine anti-emetics and had all experienced mild to moderate gastro-intestinal toxicity and so were considered suitable for inclusion in the analysis. Symptoms Twenty-six patients completed questionnaires for one or both parts of the crossover. Symptom scores prior to chemotherapy (Day 0) were similar for nabilone and prochlorperazine subjects, except for a higher proportion of the latter who reported mild retching. Table III summarizes the scores for each symptom during chemotherapy, giving the daily mean scores, and the proportion of patients with the maximum score, on either anti-emetic. Mean symptom scores were always higher and the proportion of patients with the worst scores was Vomiting episodes Although the worst symptoms were reported on Day 1, the greatest number of patients vomited on Day 2-see Table IV . There was no statistical difference between nabilone and prochlorperazine patients' vomiting on Day 1, but a significantly The median ages of patients preferring nabilone and prochlorperazine overall were 58 years and 61.5 years, and the median ECOG status for these groups was 2 and 1 respectively. There was no statistical association between sex or stage of disease and preference.
Side-effects Side-effects were commoner with nabilone than prochlorperazine-see Table VI . The commonest were drowsiness (57% on nabilone and 27% on prochlorperazine), postural dizziness (35% and 4% respectively) and light-headedness (18% of nabilone subjects only). The severity of these symptoms usually fell progressively over the 3 day period. A "drunk" feeling was reported by 5 patients (18%) on nabilone, of whom 2 found it pleasant and 3 unpleasant. Moderate euphoria occurred in 4 patients (14%) on nabilone and a "high" was observed in 2 (7%); no patients on prochlorperazine reported these sensations. Mild confusion and disorientation were seen in 3 nabilone subjects (11%) and more upsetting dysphoria in 2 (7%): however no patient had hallucinations.
The side-effects which were severe enough to cause a patient to be withdrawn from a course of nabilone, or to prefer prochlorperazine for subsequent chemotherapy in spite of better antiemetic control with nabilone, were extreme drowsiness (2 patients), severe postural dizziness (2), light-headedness (4) and unpleasant "drunk" feeling (3). The median age of patients who reported a "drunk" feeling on nabilone was 42 years; for those who experienced euphoria or a "high" it was 49.5 years. The median ages of patients who reported other side-effects were close to the whole group's. There was no significant association between anti-emetic preference and the patients' previous alcohol consumption.
There nabilone on Day 2 because of severe drowsiness, moderate postural dizziness and mild confusion: the lowest recordings were 90/60 mm Hg supine, 80/55mm Hg erect, with a pulse rate of 110/min (sinus rhythm). Within 3 days of discontinuing nabilone her BP and pulse rate had returned to normal pre-treatment levels and symptoms settled. Pulse rates did not vary significantly with either drug-the highest mean rates were 99/min for prochlorperazine and 98/min for nabilone, on Day 2. Arrhythmias were not observed.
Discussion
There has been a surge of interest in anti-emetic control for cytotoxic chemotherapy in recent years (Anonymous, 1979; Laszlo & Lucas, 1981; Frytak & Moertel, 1981) . Newer agents being evaluated are high-dose metoclopramide, dexamethasone and the cannabinoids (Gralla et al., 1981; Trounce, 1982) . Most controlled studies of the latter have hitherto been conducted in the United States; those of nabilone have demonstrated useful oral efficacy and superiority over oral prochlorperazine in mixed groups of patients with various malignancies on different chemotherapeutic regimes (Herman et al., 1979; Steele et al., 1980) . However a recent short report from a British study has suggested less satisfactory results and an unacceptably high incidence of side-effects (Cornbleet et al., 1982) .
Our study was conducted in patients with a single tumour and histological type and all undergoing identical chemotherapy of moderate emetic potential. In addition the large majority of our patients had not received prior chemotherapy, and we are reasonably certain that they were not experienced in marijuana nor were they prejudiced by being alerted to the possibility that they may be receiving a cannabis-like drug. For these reasons this study contains a higher degree of control and freedom from bias than the previously reported ones, and may be of greater relevance to clinical practice in Britain.
The results showed nabilone to be an effective oral anti-emetic agent for a 3-day chemotherapy regime containing Cyclophosphamide, Adriamycin and Etoposide, completely obviating the use of parenteral medication. For multiple-day schedules, an oral anti-emetic is clearly to be preferred to repeated parenteral doses of prophylactic or "ondemand" anti-emetic drugs, or to daily courses of high dose i.v. metoclopramide.
In this trial we placed emphasis on the patients' subjective assessment of their gastro-intestinal symptoms, including retching which is not usually assessed but which some patients find as much if not more distressing than vomiting. In the objective assessment we did not find the measurement of volume of vomitus to be sufficiently reliable to include in the analysis, as others have attempted (Gralla et al., 1981) ; the volume is also probably of less relevance to the patients than the number of vomiting or retching episodes.
Nabilone was superior in most of the evaluated parameters to oral prochlorperazine, which confirms the findings of two earlier studies. Unlike the subjects of Herman et al. (1979) , our patients and those of Steele et al. (1980) did not significantly prefer nabilone overall to prochlorperazine for subsequent chemotherapy. Since ours was a fixed-dose study, it is not possible to say whether a reduction in dose for patients experiencing troublesome side-effects would have reduced these and improved subsequent acceptability whilst retaining anti-emetic efficacy. Single doses of nabilone in man have been shown to have dose-related pharmacological effects, with 1 mg inducing relaxation and sedation but no dry mouth or hypotension (Lemberger & Rowe, 1975) .
The use of widely varying doses of both nabilone and prochlorperazine in published studies has made the interpretation of efficacy and toxicity more difficult. Herman et al., (1979) actually reported on two trials which were analysed together, in one of which patients received 6mg of nabilone and 30mg of prochlorperazine daily, and in the other 8mg of nabilone and 40mg of prochlorperazine daily. Not surprisingly, the reported toxicity of nabilone was higher than that observed by Steele et al. (1980) and our group who used a dose of 4 mg daily, and prochlorperazine at 20 mg and 30 mg daily respectively; the range and incidence of side-effects in these trials are more comparable. The results Steele et al. (1980) obtained for nabilone against non-platinum agents and low-dose platinum were also similar to ours. In their pilot study of nabilone against a variety of chemotherapeutic drugs including platinum, Cornbleet et al. (1982) used a higher starting dose of 2mg 6-hourly for the first 12h, followed by 2mg 12-hourly. This increase in dose was sufficient for the authors to find a "high incidence (55%) of significant psychotropic sideeffects."
We did not find any statistical association between age or sex and nabilone toxicity and so we suggest that the dose of nabilone be restricted to 2mg 12-hourly for most patients for adequate antiemetic control aganist non-platinum drugs, with a moderate but overall acceptable incidence of sideeffects. Indeed several patients at this dose reported pleasant mental changes, and our limited experience is that subsequent courses of nabilone at the same or lower dose (1 mg 12-hourly) retained its efficacy with no increase in toxicity. However, the long-term use of nabilone has yet to be studied.
Postural hypotension and tachycardia are important pharmacological effects of the cannabinoids (Anonymous, 1978) , but this only became a symptomatic problem in 7% of our nabilone subjects. One of the 2 patients with severe cardiovascular toxicity had a mitral valve replacement; extra caution is therefore indicated when using nabilone in patients with known cardiac disease.
Furthermore, unpredictability of the adverse effects discussed above demands the exercise of caution in all patients receiving nabilone for the first time, and we would recommend that they receive the drug under in-patient supervision at least for the first 24 hours.
